Sponsors (45)
Directs FDA to require pathogen testing (including C. botulinum), environmental sampling, rapid manufacturer reporting, record retention, and uniform inspection standards for infant formula, with final rules due in 90 days.
The bill tightens testing, reporting, and inspection requirements to better protect infants from contaminated formula, at the cost of higher compliance burdens, potential price increases, and a risk of short-term supply disruptions and implementation strain on regulators.
Parents and infants: the bill strengthens safety oversight by requiring more testing/monitoring and consistent inspection standards for all infant formula, reducing the chance contaminated product reaches babies.
Parents and public health officials: manufacturers must notify the FDA of positive test results within one business day and the FDA must notify Congress quickly, enabling faster detection and coordinated responses to safety problems.
Public health and investigators: retaining records of positive test results improves inspections and helps trace sources of contamination during investigations.
Parents and consumers: increased testing, recordkeeping, and rapid-reporting requirements raise compliance costs for infant formula manufacturers that may be passed on to shoppers as higher prices.
Parents and infants: stricter testing and faster reporting could trigger more recalls or product holds, creating short-term supply disruptions and reduced formula availability.
Regulators and public health systems: the 90-day deadline for final regulations may strain FDA resources and lead to rushed rulemaking or implementation challenges.
Based on analysis of 2 sections of legislative text.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
Introduced March 9, 2026 by Rosa L. Delauro · Last progress March 9, 2026
Requires the FDA to strengthen infant formula manufacturing rules by requiring pathogen and environmental testing of facilities and finished products (explicitly including Clostridium botulinum), faster manufacturer reporting to FDA of positive tests, retention of positive-test records, and uniform inspection/enforcement for all infant formula regardless of origin. It also requires FDA to notify key House and Senate committees within one business day of manufacturer positive finished-product test results or of serious inspection findings, and directs FDA to issue final regulations within 90 days of enactment. The bill adds new specific testing and recordkeeping duties for manufacturers, a rapid-notice requirement to FDA, and new agency-to-Congress reporting triggers to speed oversight of contamination events and inspection outcomes.